Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
PRTA
vs
S&P 500
PRTA
S&P 500
Over the past 12 months, PRTA has underperformed S&P 500, delivering a return of -20% compared to S&P 500's +15% growth.
Stocks Performance
PRTA vs S&P 500
Performance Gap
PRTA vs S&P 500
Performance By Year
PRTA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Prothena Corporation PLC
Glance View
Prothena Corporation PLC is a biotechnology company that focuses on diseases caused by harmful proteins, especially neurodegenerative disorders and certain rare amyloid-related conditions. It does not sell a broad line of commercial medicines; instead, it develops drug candidates intended to stop or slow the protein misfolding and buildup that drives these illnesses. Its main customers are not end patients in the usual retail sense. Prothena mainly works with large pharmaceutical partners, research collaborators, hospitals, and eventually physicians and health systems if its medicines reach the market. The company makes money through collaboration payments, licensing deals, research funding, and, if its programs succeed, future product sales or royalties. What makes Prothena different is its narrow focus on difficult diseases where abnormal proteins are central to the problem. That puts it in a specialized role in the drug-development chain: it takes scientific ideas from early research into clinical testing, often with partners that help fund development and may later handle large-scale commercialization.